Research Articles | Page 83 | Aplastic Anemia & MDS International Foundation

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes Jan 2019 Blood myelodysplastic syndromes (MDS)
Rethinking clinical trial endpoints in myelodysplastic syndromes. Jan 2019 Leukemia myelodysplastic syndromes (MDS)
Antithymocyte globulin and cyclosporin: standard of care also for older patients with aplastic anemia. Feb 2019 Haematologica aplastic anemia
Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. Feb 2019 Cancer Med aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. Feb 2019 Biol Blood Marrow Transplant. paroxysmal nocturnal hemoglobinuria (PNH)
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes Mar 2019 Clin Lymphoma Myeloma Leuk myelodysplastic syndromes (MDS)
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. Mar 2019 Haematologica paroxysmal nocturnal hemoglobinuria (PNH)
Clonal Hematopoiesis and therapy related MDS/AML Mar 2019 Best Practice & Research. Clinical Heamatology myelodysplastic syndromes (MDS)
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version Mar 2019 National Cancer Institute myelodysplastic syndromes (MDS)
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) Mar 2019 Leukemia Research myelodysplastic syndromes (MDS)